TransDigm Group Insider Sold Shares Worth $27,909,629, According to a Recent SEC Filing-February 2024-www.financetom.com

TransDigm Group Insider Sold Shares Worth $27,909,629, According to a Recent SEC Filing

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

TransDigm Group Insider Sold Shares Worth $27,909,629, According to a Recent SEC Filing

Jun 13, 2024 12:42 AM

03:17 AM EDT, 06/13/2024 (MT Newswires) -- Robert J Small, Director, on June 12, 2024, sold 21,210 shares in TransDigm Group ( TDG ) for $27,909,629. Following the Form 4 filing with the SEC, Small has control over a total of 681,542 shares of the company, with 15,920 shares held directly and 665,622 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1260221/000091957424003630/xslF345X03/ownership.xml

Price: 1,322.70, Change: +0.57, Percent Change: +0.04

Previous page： Moody's Secular Growth Trends Seen as Intact Despite Macro Challenges, RBC Says Next page： Rocket Pharma Reports Patient Death In Rare Disease Gene Therapy Trial, FDA Puts Clinical Hold

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Moody's Secular Growth Trends Seen as Intact Despite Macro Challenges, RBC Says

May 27, 2025

11:08 AM EDT, 05/27/2025 (MT Newswires) -- Moody's (MCO) secular growth trends are intact despite near-term macroeconomic difficulties, RBC Capital Markets said in a note Monday. Citing Moody's Chief Financial Officer Noemie Heuland, RBC said lending solutions, know-your-customer, insurance risk platforms and private credit continue to be strong. Additionally, the shift toward solution-based selling presents significant cross-sell opportunities within banking,...

Rocket Pharma Reports Patient Death In Rare Disease Gene Therapy Trial, FDA Puts Clinical Hold

May 27, 2025

Rocket Pharmaceuticals Inc ( RCKT ) announced an update Tuesday related to RP-A501, its investigational gene therapy for Danon disease, a rare X-linked dominant genetic disorder that manifests with the clinical triad of cardiomyopathy (stiff heart muscles), skeletal myopathy (weakness) and intellectual disability. A patient participating in the Phase 2 pivotal trial of RP-A501 experienced an unexpected Serious Adverse Event (SAE)....

Oklo, South Korea's KHNP enter into agreement to develop Aurora nuclear facility

May 27, 2025

May 27 (Reuters) - Nuclear technology company Oklo ( OKLO ) said on Tuesday it has signed a memorandum of understanding (MOU) with South Korea's nuclear power plant operator Korea Hydro & Nuclear Power (KHNP) to develop Oklo's ( OKLO ) planned Aurora powerhouse. Shares of Oklo ( OKLO ) were up 1.9% at $49.71 in morning trade. Oklo (...

Google agrees $36 million fine for anti-competitive deals with Australia telcos

Aug 17, 2025

SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...